Figures & data
Figure 1. Time course for urine flow in a kidney perfused without (Δ) or with 25 μg/mL of CDDP (□) or CDDP-CSA-23 (○) (equivalent to 25 μg/mL of CDDP).
Notes: Values obtained within 10 min prior to perfusion were used as control levels. All values are the mean ± SD (n = 4–5). CDDP, Cisplatin; CSA, chondroitin sulfate.
*p < 0.05 versus control; **p < 0.05 versus complex.
Figure 2. Time course for the rate of clearance of creatinine in a kidney perfused without (Δ) or with 25 μg/mL of CDDP (□) or CDDP-CSA-23 (○) (equivalent to 25 μg/mL of CDDP).
Notes: Values obtained within 10 min prior to perfusion were used as control levels. All values are the mean ± SD (n = 4–5). CDDP, Cisplatin; CSA, chondroitin sulfate.
*p < 0.05 versus control; **p < 0.05 versus complex.
Figure 3. Concentration of free platinum in urine (A) and in the kidney (B) perfused with 150 μg/mL CDDP or CDDP-CSA-23 complex (equivalent to 150 μg/mL of CDDP).
Notes: Urine was collected within the first 10 min from the perfused kidney. Values are expressed as the mean ± SD (n = 4). CDDP, Cisplatin; CSA, chondroitin sulfate.
Figure 4. Cytoprotective effects of CDDP-CSA-23 complex in HK-2 cells for 24 h (□) and 72 h (▪).
Notes: Concentrations of compounds were based on CDDP concentration. The concentration of CSA-23 alone (42 μg/mL) was equivalent to that of CSA-23 containing 5 μg/mL CDDP. Values are expressed as the mean ± SD (n = 6). CDDP, Cisplatin; CSA, chondroitin sulfate; HK-2, human proximal tubular cells.
*, **p < 0.01 compared with control and CSA-23 for 24 and 72 h, respectively.
